View Alert


Originator: CMO Messaging

From: CMO Messaging

Issue date: 14-Dec-2021 10:57:24

This alert has been issued to:
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Class 1: Immediate

Title: Withdrawal of the Recommendation for Consideration of Inhaled Budesonide as a Treatment Option for COVID-19

Broadcast content: In parallel to the publication of revised guidance from the National Institute for Health and Care Excellence (NICE), the previously published UK interim position statement covering inhaled budesonide as a treatment option for individuals with COVID infection has been withdrawn. Inhaled budesonide should no longer be considered as a treatment for COVID-19 infection other than within the context of a clinical trial. People already using budesonide for conditions other than COVID-19 should continue treatment if they test positive for COVID-19.

Additional information: NHS England and NHS Improvement Regional Offices: please cascade this alert to Community Pharmacy

Alert reference: CEM/CMO/2021/011(U)

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency